Literature DB >> 2423050

Serotonin and 5-hydroxyindoleacetic acid in brains of suicide victims. Comparison in chronic schizophrenic patients with suicide as cause of death.

E R Korpi, J E Kleinman, S I Goodman, I Phillips, L E DeLisi, M Linnoila, R J Wyatt.   

Abstract

Serotonin (5-HT) and 5-hydroxyindoleacetic acid concentrations were determined in various brain areas of nonschizophrenic suicide victims, chronic schizophrenic patients with or without suicide as the cause of death, and normal control subjects without psychiatric or neurologic disorders. Serotonin concentrations in the basal ganglia were significantly elevated in suicide victims and chronic schizophrenic patients, as were 5-hydroxyindoleacetic acid concentrations in the occipital cortex. These differences were not specific to either patient group and may have been caused by neuroleptic or antidepressant treatment. A decreased 5-HT concentration was found in the hypothalamus of nonschizophrenic suicide victims. Among the chronic schizophrenic patients, there was no significant difference in the hypothalamic 5-HT content between the suicide victims and others, indicating that low 5-HT levels in the hypothalamus are not characteristic of schizophrenic patients who died of suicide.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423050     DOI: 10.1001/archpsyc.1986.01800060088011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  13 in total

1.  Serotonin 5-HT3 receptor binding kinetics in the cortex of suicide victims are normal.

Authors:  J J Mann; V Arango; R A Henteleff; T F Lagattuta; D T Wong
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites.

Authors:  J J Mann; R A Henteleff; T F Lagattuta; J A Perper; S Li; V Arango
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity.

Authors:  C A Stockmeier; L A Shapiro; G E Dilley; T N Kolli; L Friedman; G Rajkowska
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

4.  Smoking-associated changes in the serotonergic systems of discrete regions of human brain.

Authors:  M E Benwell; D J Balfour; J M Anderson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Serotonin receptor 1A knockout: an animal model of anxiety-related disorder.

Authors:  S Ramboz; R Oosting; D A Amara; H F Kung; P Blier; M Mendelsohn; J J Mann; D Brunner; R Hen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 6.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

7.  Impulsivity, gender, and the platelet serotonin transporter in healthy subjects.

Authors:  Donatella Marazziti; Stefano Baroni; Irene Masala; Francesca Golia; Giorgio Consoli; Gabriele Massimetti; Michela Picchetti; Mario Catena Dell'osso; Gino Giannaccini; Laura Betti; Antonio Lucacchini; Antonio Ciapparelli
Journal:  Neuropsychiatr Dis Treat       Date:  2010-02-03       Impact factor: 2.570

8.  Brain gamma-aminobutyrate transaminase and monoamine oxidase activities in suicide victims.

Authors:  F Sherif; J Marcusson; L Oreland
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

Review 9.  The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine.

Authors:  J N Joyce
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 10.  The role of serotonin in schizophrenia: an overview of the nomenclature, distribution and alterations of serotonin receptors in the central nervous system.

Authors:  D C Ohuoha; T M Hyde; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.